$KDNY

Chinook Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Commercial Services
  • Miscellaneous Commercial Services
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$25.1 -

Extented Hours

VOLUME

1,265,532

DAY RANGE

24.1968 - 25.92

52 WEEK

15.08 - 27.44

Join Discuss about KDNY with like-minded investors

See 5 more KDNY posts
profile
@dros #droscrew
recently

Upgrades 3/6: $EXT $EMR $HCP $MNST $MTH $REVG $TX $VIR .. Downgrades 3/6: $AMOT $BIRD $DHI $EMBK $EURN $HR $IHG $KBH $NRGV $PRAX $RH $SI $SWX $WEN +Initiations 3/6: $AAPL $ATHX $AVID $KDNY $MRK $NXT $PIXY ..

60 Replies 7 👍 12 🔥

profile
@dros #droscrew
recently

+Initiations 1/6: $ARDX $AYX $DNMR $KDNY $LAZR $NBTX $NLTX $OPEN $PTGX $SCYX $SEIC $SRRK $VINC $VLDR $VSTO $WELL . -Initiations 1/6: $SCCO

122 Replies 6 👍 6 🔥

profile
@dros #droscrew
recently

+Initiations 10/7: $CNTG $DT $HEI $IDYA $IIVI $KDNY $NEWR $NFIN $NOVA $PEN $SPWR $SWI -Initiations 10/7: $GSKY

104 Replies 6 👍 13 🔥

profile
@Pyrognosis #droscrew
recently

New option listings for October 6th include Chinook Therapeutics Inc (KDNY) and Palantir Technologies Inc (PLTR) (Class A Stock) (PLTR). Option delistings effective October 6th include Aduro Biotech Inc ( ADRO) , TD Ameritrade Holding Corporation ( AMTD) , and Noble Energy Inc (NBL).

69 Replies 10 👍 9 🔥

Load more...

Key Metrics

Market Cap

1.69 B

Beta

0.99

Avg. Volume

819.31 K

Shares Outstanding

66.89 M

Yield

0%

Public Float

0

Next Earnings Date

2023-08-07

Next Dividend Date

Company Information

chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.

CEO: Stephen Isaacs

Website:

HQ: 740 Heinz Ave Berkeley, 94710-2748 California

Related News